

Main Article

Dr D Westby takes responsibility for the integrity of the content of the paper

Cite this article: Westby D, O'Connell N, Powell J, Fenton JE. The changing nature of paediatric otomycosis in the mid-west of Ireland. *J Laryngol Otol* 2020;**134**:592–596. <https://doi.org/10.1017/S0022215120001164>

Accepted: 12 April 2020
First published online: 27 July 2020

Key words:

Otomycosis; Fluoroquinolones; Pediatrics; Otitis Externa; Fungal Infections

Author for correspondence:

Dr Daniel Westby, Department of Surgery, University Hospital Limerick, Limerick, Ireland
E-mail: d.westby1@hotmail.com

The changing nature of paediatric otomycosis in the mid-west of Ireland

D Westby¹, N O'Connell², J Powell² and J E Fenton^{3,4}

Departments of ¹Surgery, ²Microbiology, ³Otolaryngology, University Hospital Limerick and ⁴Graduate Entry Medical School, University of Limerick, Ireland

Abstract

Background. Fungal otitis externa is prevalent in tropical and sub-tropical climates; however, over the past two decades, there has been a reported increase in the prevalence of otomycosis in paediatric patients from more temperate climates. This study aimed to review the children diagnosed with otomycosis at the University Hospital Limerick with reference to frequency, causative organism, predisposing factors and management.

Methods. A retrospective review was conducted of paediatric patients from 2001 to 2015. Patients with positive fungal ear swabs and a diagnosis of otomycosis were identified.

Results. Ninety-three patients were positive for candida (mean age, 5.8 years), 10 patients were positive for aspergillus (mean age, 9.1 years) and 1 patient had mixed fungal infection containing both fungi. There was a positive correlation between a diagnosis of otomycosis and prior treatment with topical fluoroquinolones ($r = 0.8$; $p < 0.01$).

Conclusion. The incidence of otomycosis has been increasing since 2001, which correlates with an increase in the use of topical fluoroquinolones. Previous studies identify aspergillus as the commonest causative fungi; however, this study found that candida was the commonest isolated fungi in the paediatric population.

Introduction

Fungal otitis externa, or otomycosis, is not typically associated with the Irish climate. It is more prevalent in hot and humid climates, which provide optimal conditions for the growth of fungi. Jackman *et al.*¹ stated that 'the number of paediatric patients diagnosed with otomycosis has increased over the past decade'. At the University Hospital Limerick, Ireland, there has been a noticeable but anecdotal increase in positive fungal ear infections during the past two decades.

Fungal and bacterial otitis externa typically present with unilateral pruritis, otorrhoea, otalgia and changes in hearing.² Otorrhoea is a cardinal feature to several pathologies of the external auditory canal and the middle ear; for example, acute, chronic and malignant otitis externa, acute otitis media, chronic suppurative otitis media, and cholesteatoma, while also occurring in otomycosis and following tympanostomy tube insertion.³

Traditionally, the incidence rate of otomycosis has been low in western Europe, with 16 and 24 per cent of cases diagnosed by general practitioners and ENT departments, respectively.⁴ Thus, when we consider the common clinical features, it is reasonable to understand how it can easily go misdiagnosed at initial presentation, and hence why ineffective treatment modalities are subsequently implemented.^{5,6} The majority of confirmed fungal otitis externa cases are identified in persistently discharging ears following topical antibiotic treatment for assumed otitis media or externa, as found by Llor *et al.*⁷

Several studies have reported aspergillus and candida species as the commonest isolated organisms in otomycosis, with aspergillus species being the predominant fungi.^{8–11}

Otorrhoea is a recognised post-operative sequela following grommet insertion; it is estimated to occur in one out of six patients within six weeks of surgery.¹² Martin *et al.*¹³ discovered that in the last decade there has been an increase in positive fungal cultures in cases of otorrhoea following grommet insertion, with candida being the commonest causative organism. This evidence is further supported by Vennewald *et al.*,¹⁰ who determined that the presence of fungal species on culture is of infectious cause rather than contamination.

Topical fluoroquinolones, such as ciprofloxacin, have been shown to be as effective as topical aminoglycosides, like gentamycin, in the treatment of otitis media and otitis externa.¹⁴ Topical ciprofloxacin has been favoured over gentamycin in recent years, in light of minimal ototoxicity and a favourable side-effect profile. However, it has been hypothesised that the neutral pH of ciprofloxacin creates a less acidic environment in the external auditory canal, thus encouraging the proliferation of opportunistic fungi.¹⁵

Currently, there is no Food and Drug Administration approved treatment for a positive diagnosis of otomycosis. The azole class of antifungals, such as clotrimazole, fluconazole, ketoconazole and miconazole, is effective and with no ototoxic complications.¹⁵

This study aimed to review the children diagnosed with otomycosis at the University Hospital Limerick from 2001 to 2015, with reference to frequency, causative organism, predisposing factors and management.

Materials and methods

A retrospective review was carried out of cases from 2001 to 2015 in the ENT Department at the University Hospital Limerick, Ireland. The study population consisted of paediatric patients, aged 0–14 years, with ear swabs positive for fungal otitis externa, as identified by the Microbiology Department at the University Hospital Limerick. The causative organisms, frequency and distribution of otitis externa cases with positive fungal swab results were obtained. The population was divided into two cohorts: those treated in primary care and those treated by the ENT Department at the University Hospital Limerick, the latter of which is the focus of this study.

Patients identified as having positive fungal swabs who were treated by the ENT Department were reviewed in relation to: (1) the number of positive diagnoses per year; (2) causative organisms; (3) preceding use of topical fluoroquinolones; (4) the presence of a tympanostomy tube at time of diagnosis (inclusive of patients prescribed topical fluoroquinolones for otorrhoea following tympanostomy tube insertion); and (5) the treatment of otomycosis in these patients.

Statistical analysis was carried out using Microsoft Excel® and RStudio software. The relationship between the use of topical fluoroquinolones and incidence of fungal otitis media was examined using Spearman's rank-order correlation.

Results

A total of 104 patients were diagnosed with otomycosis based on positive fungal ear swabs from 2001 to 2015 at the University Hospital Limerick. The mean (\pm standard deviation) age was 7 ± 4.67 years, with an equal number of male and female patients. The positive cases of fungal otitis media were unilateral (37 right side, 27 left side). Nine patients were found to have pre-existing inner-ear pathology or dysfunction. One patient had eczema, a co-morbidity affecting the external auditory canal, making them more susceptible to otomycosis (Table 1).

It is evident from the swab results that there has been an increase in otomycosis over the past two decades, with a peak incidence in 2009 (Figure 1). The population was divided into two groups: cases treated in primary care ($n = 33$) and cases treated by the ENT Department at the University Hospital Limerick ($n = 71$). Figure 2 illustrates the sample size treated by the ENT Department at the University Hospital Limerick and that group subsequently became the focus group of this study.

Overall, candida ($n = 93$) was the commonest causative organism in comparison to aspergillus ($n = 10$), with one case of mixed infection containing both candida and aspergillus (Figure 1). When we compare this to the cases treated specifically by the ENT Department at the University Hospital Limerick, the numbers naturally decrease. However, the hierarchy of causative organism remains unchanged, with 62 patients positive for candida and 8 positive for aspergillus, with a single case of mixed fungal infection (Figure 2). The distribution of positive fungal swabs also reveals an increased incidence of fungal otitis externa from 2001 to 2015; however, the peak incidence of this cohort occurred in 2006.

Table 1. Clinical and demographic data for patients with positive fungal ear swabs*

Parameter	Value
Age (mean \pm SD; years)	7 ± 4.67
Males/females (n)	32/32
Ear swab (n)	
– Right	37
– Left	27
Pre-existing ear pathology (n)	
– Mastoid surgery	4
– Hearing aid	3
– Eczema	1
– Cochlear implant	1

*For patients presenting from 2001 to 2015 at the University Hospital Limerick ($n = 64$). SD = standard deviation

Patients treated by the ENT Department at the University Hospital Limerick were analysed according to the presence of a tympanostomy tube at time of diagnosis, with and without concurrent use of ciprofloxacin (Figure 3). Of the patients with positive fungal ear swabs treated with topical ciprofloxacin ($n = 32$), 19 were found to have tympanostomy tubes in situ at the time of diagnosis (grommets plus ciprofloxacin group), compared with 13 patients in the ciprofloxacin without grommets group, while the remaining patients had no documented evidence of topical ciprofloxacin use (14 of these patients had tympanostomy tubes in situ (grommets without ciprofloxacin group). Eighteen patients were found to have no documented evidence of topical ciprofloxacin use or tympanostomy tube insertion prior to a positive ear swab for fungal otitis externa.

Thirty-two patients had documented evidence of being treated with topical ciprofloxacin prior to a diagnosis of fungal otitis externa. A positive relationship (Spearman's rho correlation, $r = 0.8$) between a diagnosis of otomycosis and prior treatment with topical ciprofloxacin was found. The correlation coefficient was statistically significant ($p < 0.01$).

Several methods have been implemented for the treatment of otomycosis. The data gathered in this study revealed that aural toilet and the insufflation of mastoid powder is an effective modality for the treatment of fungal otitis externa. The majority of patients diagnosed with fungal otitis externa at the University Hospital Limerick were treated with mastoid powder ($n = 40$) compared to other methods ($n = 24$) (Figure 4). Mastoid powder contains a drying agent, ciprofloxacin, clotrimazole and a steroid. Based on expert opinion, it is effective in the eradication of common fungal pathogens, such as candida and aspergillus, while also providing antimicrobial coverage and symptomatic control of an inflamed external auditory canal with the inclusion of a steroid.¹⁶

Discussion

The number of confirmed cases of otomycosis, based on positive fungal ear swabs, has increased at the University Hospital Limerick from 2001 to 2015. Swab results, obtained from the Microbiology Department of the University Hospital Limerick, indicate that candida species were the most prevalent fungi isolated, followed by aspergillus species. These findings are important, as they confirm the initial




Fig. 1. Overall incidence of otomycosis from 2001 to 2015 ($n = 104$). This graph illustrates the increase in fungal otitis externa, with a peak incidence in 2009. It is also evident that candida species predominates as the causative organism ($n = 93$) (aspergillus species, $n = 10$; mixed, $n = 1$).




Fig. 2. Distribution of patients diagnosed with otomycosis who were treated specifically by the ENT Department at University Hospital Limerick ($n = 71$). The distribution and predominate causative organism are comparable to what is shown in Figure 1. Documentation could not be located for 7 patients; therefore, the sample size was further reduced to 64 cases.

hypothesis that fungal otitis externa has increased among the paediatric population, and they identify candida species as the most prevalent organism, rather than aspergillus, which is in contrast to current literature.^{6,9–11,17} One hypothesis that might explain the prevalence of candida over aspergillus as the commonest causative organism in this study concerns the Irish climate, as most investigations on otomycosis were based in tropical and sub-tropical regions.

It has been stated that fungal otitis externa is commonly diagnosed following antimicrobial treatment for presumed otitis media infection which typically presented with a discharging ear.¹⁸ Topical fluoroquinolone use has increased in recent years because it has been found to be as effective as topical agents such as gentamicin, but with no ototoxicity.¹⁴ Literature has suggested that the increased use of topical ciprofloxacin may be a contributing factor in the rising numbers of fungal otitis externa seen over the past two decades.¹

The current study found a statistically significant ($p < 0.01$) positive correlation ($r = 0.8$) between fungal otitis externa

and prior topical ciprofloxacin use (Figure 3). Although the aetiology of otomycosis is multifactorial, we can say with confidence that prior use of topical ciprofloxacin should be considered as a contributing factor. This correlation is supported by the fact that topical fluoroquinolones have a neutral pH, which decreases irritation of the external auditory canal, but in turn facilitates the growth of opportunistic fungi such as candida and aspergillus.¹

Grommet insertion is a frequently performed procedure in the paediatric population, and the most common associated complication is post-operative otorrhoea.^{12,19,20} The literature has shown that post-operative otorrhoea caused by fungal species accounts for less than 5 per cent of cases.^{21,22}

Thirty-three patients in the current study had grommets in situ when they presented with a discharging ear and were subsequently found to have positive fungal ear swabs. Nineteen of these patients were treated with topical ciprofloxacin prior to diagnosis. This is not unreasonable as topical ciprofloxacin is recommended for antimicrobial prophylaxis following grommet insertion.²³ Fourteen patients were found to have




Fig. 3. Otomycosis in the presence of tympanostomy tubes. ‘G + C’ = patients with grommets who were treated with ciprofloxacin prior to an otomycosis diagnosis; ‘C - G’ = patients treated with ciprofloxacin but who did not have grommets; ‘G - C’ = patients with grommets with no documented evidence of topical ciprofloxacin use; ‘Neither’ = no documented evidence of topical ciprofloxacin use or tympanostomy tube insertion.




Fig. 4. Otomycosis treatment methods (total n = 64). Forty patients were treated with aural toilet and mastoid powder; 24 received other treatments.

grommets in situ at the time of diagnosis; however, there was no documented evidence of prior topical ciprofloxacin use. Eighteen patients diagnosed with otomycosis had no documented evidence of grommets in situ or prior topical ciprofloxacin use, indicating that there are other contributing factors related to fungal otitis externa. Although the sample size is not large enough for statistical analysis, these findings are in line with the correlation between otomycosis and prior ciprofloxacin use.

As already stated, there is no Food and Drug Administration approved treatment for fungal otitis externa; however, several studies have shown that other antifungals, such as clotrimazole, are effective as monotherapy, or in conjunction with one or more alternative methods.¹⁵ Literature states that fungal otitis externa can be effectively treated by: discontinuing any antimicrobial treatment, or performing

debridement or aural toilet, and subsequently applying a topical antifungal or combination powder.^{1,10,15,16}

- There has been an increased incidence in fungal otitis externa in recent years
- *Candida* was found to be the commonest causative organism
- The pathogenesis of otomycosis is multifactorial; however, this study indicates that topical fluoroquinolones play a key role
- Multimodal approaches are important for the successful eradication of offending fungi
- Combination powders are favourable for symptomatic control, and provide adequate coverage for both bacterial and fungal pathogens

Aural toilet followed by insufflation of a combination powder has been the approach used in the ENT Department at the University Hospital Limerick. The combination powder recipe was obtained via personal communication from a North American otorhinolaryngology expert. This ototopical powder contains ciprofloxacin, clotrimazole, dexamethasone and boric acid.¹⁶ The clinical results to date indicate that this method is effective in achieving a clinical cure for fungal otitis externa. The method was implemented in two-thirds of the University Hospital Limerick ENT Department population, with successful outcomes; thus, it can be considered a promising approach in the field of ENT.

Conclusion

This study revealed that the incidence of otomycosis in Ireland has increased in recent years. *Candida* was found to be the commonest causative organism, which is contrary to findings reported in the literature. This increase can be attributed to a rise in the use of topical fluoroquinolones such as ciprofloxacin given their favourable side-effect profile. Aural toilet and insufflation of a combination powder shows promising results, not only in the eradication of fungal otitis externa, but potentially as a routine post-operative prophylactic treatment. Further large-scale studies are needed to fully elucidate the role of combination powders, such as the ototopical powder used in this study, and increase their use in the field of ENT.

Competing interests. None declared

References

- 1 Jackman A, Ward R, April M, Bent J. Topical antibiotic induced otomycosis. *Int J Pediatr Otorhinolaryngol* 2005;**69**:857–60
- 2 Gohar M, Anwar K, Gohar M. Otomycosis; clinical features, predisposing factors and treatment implications. *Pak J Med Sci* 2014;**30**:564–7
- 3 Rosenfeld R, Schwartz S, Cannon C, Roland P, Simon G, Kumar K *et al.* Clinical Practice Guideline: acute otitis externa. *Otolaryngol Head Neck Surg* 2014;**150**(suppl 1):S1–24
- 4 Gutiérrez PH, Álvarez SJ, Sanudo E, García LGC, Sánchez CR, Vallejo Valdezate LA. Presumed diagnosis: otomycosis. A study of 451 patients [in Spanish]. *Acta Otorrinolaringol Esp* 2005;**56**:181–6
- 5 Fasanla J, Ibeke T, Onakoya P. Otomycosis in Western Nigeria. *Mycoses* 2008;**51**:67–70
- 6 Jyothi R, Shah W, Mohan M, Sathyaki S, Mannur S, Nazir F *et al.* Otomycosis – mycological spectrum aetio-pathological factors and management. *J Evol Med Dent Sci* 2014;**3**:4850–8
- 7 Llor C, McNulty C, Butler C. Ordering and interpreting ear swabs in otitis externa. *BMJ* 2014;**349**:g5259
- 8 Jia X, Liang Q, Chi F, Cao W. Otomycosis in Shanghai: aetiology, clinical features and therapy. *Mycoses* 2011;**55**:404–9
- 9 Kazemi A, Majidinia M, Jaafari A, Ayatollahi Mousavi S, Zarei Mahmoudabadi A, Alikhah H. Etiologic agents of otomycosis in the north-western area of Iran. *Jundishapur J Microbiol* 2015;**8**:e21776

- 10 Vennewald I, Klemm E. Otomycosis: diagnosis and treatment. *Clin Dermatol* 2010;**28**:202–11
- 11 Nowrozi H, Arabi FD, Mehraban HG, Tavakoli A. Mycological and clinical study of otomycosis in Tehran, Iran. *Bull Env Pharmacol Life Sci* 2018;**3**: 29–31
- 12 Kinsella J, Fenton J, Donnelly M, McShane D. Tympanostomy tubes and early post-operative otorrhea. *Int J Pediatr Otorhinolaryngol* 1994;**30**:111–14
- 13 Martin T, Kerschner J, Flanary V. Fungal causes of otitis externa and tympanostomy tube otorrhea. *Int J Pediatr Otorhinolaryngol* 2005;**69**:1503–8
- 14 Sabater F, Maristany M, Villar E, Traserra J. Prospective double-blind randomized study of the efficacy and tolerance of topical ciprofloxacin vs topical gentamicin in the treatment of simple chronic otitis media and diffuse external otitis [in Spanish]. *Acta Otorrinolaringol Esp* 1996;**47**:217–20
- 15 Munguia R, Daniel S. Otological antifungals and otomycosis: a review. *Int J Pediatr Otorhinolaryngol* 2008;**72**:453–9
- 16 Coates H, Hawke M, Manning SC, Vesterhauge S, Haynes DS, Deitmer T. Strategies for managing granulation tissue. *Ear Nose Throat J* 2003;**82** (8 suppl 2):21–4
- 17 Viswanatha B, Naseeruddin K. Fungal infections of the ear in immunocompromised host: a review. *Mediterr J Hematol Infect Dis* 2011;**3**: e2011003
- 18 Seedat R. The discharging ear: a practical approach. *CME* 2004;**22**: 246–9
- 19 Garcia P, Gates G, Schechtman K. Does topical antibiotic prophylaxis reduce post-tympanostomy tube otorrhea? *Ann Otol Rhinol Laryngol* 1994;**103**:54–8
- 20 Hochman J, Blakley B, Abdoh A, Aleid H. Post-tympanostomy tube otorrhea: a meta-analysis. *Otolaryngol Head Neck Surg* 2006;**135**:8–11
- 21 Roland P, Parry D, Stroman D. Microbiology of acute otitis media with tympanostomy tubes. *Otolaryngol Head Neck Surg* 2005;**133**:585–95
- 22 Dohar J, Garner E, Nielsen R, Biel M, Seidlin M. Topical ofloxacin treatment of otorrhea in children with tympanostomy tubes. *Arch Otolaryngol Head Neck Surg* 1999;**125**:537–45
- 23 Morpeth J, Bent J, Watson T. A comparison of Cortisporin and ciprofloxacin otic drops as prophylaxis against post-tympanostomy otorrhea. *Int J Pediatr Otorhinolaryngol* 2001;**61**:99–104